The propionic acid and butyric acid in serum but not in feces are increased in patients with diarrhea-predominant irritable bowel syndrome

Abstract Background Short-chain fatty acids (SCFAs) alteration have been reported in irritable bowel syndrome (IBS), but the results are conflicting. Our study aims to explore the alteration of SCFAs in patients with diarrhea-predominant IBS (IBS-D) and their potential role in the occurrence and dev...

Full description

Bibliographic Details
Main Authors: Zhenyi Tian, Xiaojun Zhuang, Mei Luo, Wei Yin, Lishou Xiong
Format: Article
Language:English
Published: BMC 2020-03-01
Series:BMC Gastroenterology
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12876-020-01212-3
id doaj-7bf760cf36ac40c197d55e45607e0433
record_format Article
spelling doaj-7bf760cf36ac40c197d55e45607e04332020-11-25T03:47:52ZengBMCBMC Gastroenterology1471-230X2020-03-012011810.1186/s12876-020-01212-3The propionic acid and butyric acid in serum but not in feces are increased in patients with diarrhea-predominant irritable bowel syndromeZhenyi Tian0Xiaojun Zhuang1Mei Luo2Wei Yin3Lishou Xiong4Department of Gastroenterology and Hepatology, the First Affiliated Hospital of Sun Yat-sen UniversityDepartment of Gastroenterology and Hepatology, the First Affiliated Hospital of Sun Yat-sen UniversityDepartment of Gastroenterology and Hepatology, the First Affiliated Hospital of Sun Yat-sen UniversityDepartment of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen UniversityDepartment of Gastroenterology and Hepatology, the First Affiliated Hospital of Sun Yat-sen UniversityAbstract Background Short-chain fatty acids (SCFAs) alteration have been reported in irritable bowel syndrome (IBS), but the results are conflicting. Our study aims to explore the alteration of SCFAs in patients with diarrhea-predominant IBS (IBS-D) and their potential role in the occurrence and development of IBS. Methods We recruited patients with IBS-D defined by Rome IV criteria and age-and-gender matched healthy controls (HCs). A headspace solid-phase microextraction gas chromatography–mass spectrometric (HS-SPME-GC-MS) method was developed for the analysis of acetic, propionic and butyric acid in feces and serum. Results Compared with HCs, the levels of the serum propionate (2.957 ± 0.157 vs 2.843 ± 0.098 mmol/L, P = 0.012) and butyrate (2.798 ± 0.126 vs 2.697 ± 0.077 mmol/L, P = 0.012) were significantly higher in IBS-D group. No significant differences were found among two groups with regard to the concentration of fecal acetate (4.953 ± 1.065 vs 4.774 ± 1.465 mg/g, P = 0.679), propionate (6.342 ± 1.005 vs 6.282 ± 1.077 mg/g, P = 0.868) and butyrate (2.984 ± 0.512 vs 3.071 ± 0.447 mg/g, P = 0.607). Conclusions Metabolites of gut microbiota, the propionic and butyric acid, are increased in patients with IBS-D in serum but not in feces. It suggests that propionic and butyric acid might be associated with the occurrence and development of IBS.http://link.springer.com/article/10.1186/s12876-020-01212-3Gut microbiotaDiarrhea-predominant IBSShort-chain fatty acids
collection DOAJ
language English
format Article
sources DOAJ
author Zhenyi Tian
Xiaojun Zhuang
Mei Luo
Wei Yin
Lishou Xiong
spellingShingle Zhenyi Tian
Xiaojun Zhuang
Mei Luo
Wei Yin
Lishou Xiong
The propionic acid and butyric acid in serum but not in feces are increased in patients with diarrhea-predominant irritable bowel syndrome
BMC Gastroenterology
Gut microbiota
Diarrhea-predominant IBS
Short-chain fatty acids
author_facet Zhenyi Tian
Xiaojun Zhuang
Mei Luo
Wei Yin
Lishou Xiong
author_sort Zhenyi Tian
title The propionic acid and butyric acid in serum but not in feces are increased in patients with diarrhea-predominant irritable bowel syndrome
title_short The propionic acid and butyric acid in serum but not in feces are increased in patients with diarrhea-predominant irritable bowel syndrome
title_full The propionic acid and butyric acid in serum but not in feces are increased in patients with diarrhea-predominant irritable bowel syndrome
title_fullStr The propionic acid and butyric acid in serum but not in feces are increased in patients with diarrhea-predominant irritable bowel syndrome
title_full_unstemmed The propionic acid and butyric acid in serum but not in feces are increased in patients with diarrhea-predominant irritable bowel syndrome
title_sort propionic acid and butyric acid in serum but not in feces are increased in patients with diarrhea-predominant irritable bowel syndrome
publisher BMC
series BMC Gastroenterology
issn 1471-230X
publishDate 2020-03-01
description Abstract Background Short-chain fatty acids (SCFAs) alteration have been reported in irritable bowel syndrome (IBS), but the results are conflicting. Our study aims to explore the alteration of SCFAs in patients with diarrhea-predominant IBS (IBS-D) and their potential role in the occurrence and development of IBS. Methods We recruited patients with IBS-D defined by Rome IV criteria and age-and-gender matched healthy controls (HCs). A headspace solid-phase microextraction gas chromatography–mass spectrometric (HS-SPME-GC-MS) method was developed for the analysis of acetic, propionic and butyric acid in feces and serum. Results Compared with HCs, the levels of the serum propionate (2.957 ± 0.157 vs 2.843 ± 0.098 mmol/L, P = 0.012) and butyrate (2.798 ± 0.126 vs 2.697 ± 0.077 mmol/L, P = 0.012) were significantly higher in IBS-D group. No significant differences were found among two groups with regard to the concentration of fecal acetate (4.953 ± 1.065 vs 4.774 ± 1.465 mg/g, P = 0.679), propionate (6.342 ± 1.005 vs 6.282 ± 1.077 mg/g, P = 0.868) and butyrate (2.984 ± 0.512 vs 3.071 ± 0.447 mg/g, P = 0.607). Conclusions Metabolites of gut microbiota, the propionic and butyric acid, are increased in patients with IBS-D in serum but not in feces. It suggests that propionic and butyric acid might be associated with the occurrence and development of IBS.
topic Gut microbiota
Diarrhea-predominant IBS
Short-chain fatty acids
url http://link.springer.com/article/10.1186/s12876-020-01212-3
work_keys_str_mv AT zhenyitian thepropionicacidandbutyricacidinserumbutnotinfecesareincreasedinpatientswithdiarrheapredominantirritablebowelsyndrome
AT xiaojunzhuang thepropionicacidandbutyricacidinserumbutnotinfecesareincreasedinpatientswithdiarrheapredominantirritablebowelsyndrome
AT meiluo thepropionicacidandbutyricacidinserumbutnotinfecesareincreasedinpatientswithdiarrheapredominantirritablebowelsyndrome
AT weiyin thepropionicacidandbutyricacidinserumbutnotinfecesareincreasedinpatientswithdiarrheapredominantirritablebowelsyndrome
AT lishouxiong thepropionicacidandbutyricacidinserumbutnotinfecesareincreasedinpatientswithdiarrheapredominantirritablebowelsyndrome
AT zhenyitian propionicacidandbutyricacidinserumbutnotinfecesareincreasedinpatientswithdiarrheapredominantirritablebowelsyndrome
AT xiaojunzhuang propionicacidandbutyricacidinserumbutnotinfecesareincreasedinpatientswithdiarrheapredominantirritablebowelsyndrome
AT meiluo propionicacidandbutyricacidinserumbutnotinfecesareincreasedinpatientswithdiarrheapredominantirritablebowelsyndrome
AT weiyin propionicacidandbutyricacidinserumbutnotinfecesareincreasedinpatientswithdiarrheapredominantirritablebowelsyndrome
AT lishouxiong propionicacidandbutyricacidinserumbutnotinfecesareincreasedinpatientswithdiarrheapredominantirritablebowelsyndrome
_version_ 1724501591975788544